Rigel Pharma (RIGL): Restructuring A Positive - Jefferies

September 16, 2016 7:55 AM EDT
Get Alerts RIGL Hot Sheet
Price: $2.70 +2.66%

Rating Summary:
    6 Buy, 5 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 20 | Down: 36 | New: 11
Trade RIGL Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Jefferies analyst, Eun Yang, reiterated her Buy rating on shares of Rigel Pharmaceuticals (NASDAQ: RIGL) and raised the price target to $9 from $8.50 after the company announced a cost restructuring to prioritize fostamatinib commercialization. There are no changes planned for the development plans of IRAK inhibitor R191 however.

Yesterday, RIGL announced a ~38% workforce reduction (46 positions), largely in research, which is expected to complete by 12/15/16. RIGL expects the reduction to yield ~$17M-$20M in cost savings annually following a one-time $5.7M severance charge in 3Q16. The company will retain a smaller research organization to continue active programs (e.g., fosta in IgAN & AIHA, R191). RIGL also announced retirement of co-founder/EVP & president of discovery and research Donald Payan, and appointment of Eldon Mayer as EVP & CCO. Mr. Mayer previously held commercial roles at Questcor Pharmaceuticals, Connetics Corporation, Chiron Corpoartion, Alza Corporation & Schering-Plough.

For an analyst ratings summary and ratings history on Rigel Pharmaceuticals click here. For more ratings news on Rigel Pharmaceuticals click here.

Shares of Rigel Pharmaceuticals closed at $3.45 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Management Changes, Management Comments

Related Entities

Jefferies & Co, Layoffs

Add Your Comment